DEA Schedule I Research Exemption Pathway
Researchers can obtain DEA Schedule I researcher registration and FDA authorization to conduct clinical psilocybin research — the only domestic pathway for lawful psilocybin administration to humans.
The Problem
Schedule I classification is supposed to mean 'no accepted medical use and no safe use' — but research is how you establish those things. This circular problem has historically slowed psilocybin research. The research exemption pathway exists but involves multiple regulatory layers and significant institutional requirements.
The Solution
Researchers can legally administer psilocybin to human subjects by: (1) obtaining DEA Schedule I researcher registration (Form 225); (2) obtaining FDA authorization through an Investigational New Drug (IND) application or IND exemption; (3) receiving IRB approval; (4) procuring psilocybin from DEA-licensed manufacturers or manufacturers. The FDA has also granted Breakthrough Therapy Designation to COMPASS Pathways and Usona Institute, expediting their development pathways.
Legal Basis
21 U.S.C. § 823(f) (DEA researcher registration). 21 C.F.R. Part 312 (FDA IND regulations). FDA Breakthrough Therapy Designation process (21st Century Cures Act 2016). IRB regulations (45 C.F.R. Part 46).
Risk Assessment
Extremely low legal risk for compliant academic/clinical researchers. High administrative burden. Ongoing DEA and FDA compliance requirements. Procurement restricted to licensed manufacturers. Non-compliance with researcher registration conditions creates criminal liability. Off-protocol use of research-obtained psilocybin is a serious federal crime.